Grube Eberhard, Buellesfeld Lutz
HELIOS Heart Center Siegburg, Department of Cardiology/Angiology, Ringstrasse 49, 53721 Siegburg, Germany.
Expert Rev Med Devices. 2006 Nov;3(6):731-41. doi: 10.1586/17434440.3.6.731.
Drug-eluting stent technology consisting of a bare metal stent, carrier coating, bioactive drug and delivery system, offers an almost infinite range of possible device configurations. A growing understanding of the mechanisms of restenosis allows for the design of synergistic functions within these components, thus providing a basis for new and improved products. The BioMatrix stent (Biosensors Interventional Technologies Pte Ltd., Singapore) elutes the new sirolimus derivative Biolimus A9 from a biodegradable polylactic acid polymer. Biolimus A9 possesses enhanced anti-inflammatory and antiproliferative activity with an improved pharmacokinetic profile. Permanent polymer-carrier-based platforms may be associated with inflammation, late thrombosis and restenosis. The BioMatrix, with its asymmetric and abluminal coating, releases Biolimus A9 into the vessel wall while the polylactic acid polymer is resorbed by surrounding tissues. Clinical studies have demonstrated the BioMatrix to be well tolerated and effective, and it has now become the subject of an aggressive clinical program.
药物洗脱支架技术由裸金属支架、载体涂层、生物活性药物和输送系统组成，提供了几乎无限多种可能的器械配置。对再狭窄机制的认识不断加深，使得能够在这些组件中设计协同功能，从而为新型和改进产品提供了基础。BioMatrix支架（新加坡生物传感器介入技术私人有限公司）从可生物降解的聚乳酸聚合物中洗脱新型西罗莫司衍生物Biolimus A9。Biolimus A9具有增强的抗炎和抗增殖活性以及改善的药代动力学特征。基于永久性聚合物载体的平台可能与炎症、晚期血栓形成和再狭窄有关。BioMatrix具有不对称和管腔外涂层，在聚乳酸聚合物被周围组织吸收的同时，将Biolimus A9释放到血管壁中。临床研究表明BioMatrix耐受性良好且有效，它现在已成为一项积极的临床项目的研究对象。
